EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSBTAG00000018984
Gene Symbol: PIK3CD
26 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSBTAG00000020848
Gene Symbol: PIK3CG
15 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSBTAG00000007758
Gene Symbol: PDE10A
8 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSBTAG00000017260
Gene Symbol: PDE3A
4 Enzyme and pathways 5 Cross references
270 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSBTAG00000005218
Gene Symbol: PDE3B
14 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSBTAG00000012032
Gene Symbol: PDE4A
7 Enzyme and pathways 5 Cross references
262 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSBTAG00000008636
Gene Symbol: PDE4B
6 Enzyme and pathways 5 Cross references
312 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSBTAG00000010652
Gene Symbol: PDE4C
7 Enzyme and pathways 5 Cross references
100 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSBTAG00000000494
Gene Symbol: PDE4D
7 Enzyme and pathways 5 Cross references
248 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSBTAG00000024888
Gene Symbol: PDE5A
12 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSBTAG00000015888
Gene Symbol: PDE7B
4 Enzyme and pathways 5 Cross references
186 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSBTAG00000021899
Gene Symbol: PDE9A
4 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).